KUALA LUMPUR (Sept 3): Apex Healthcare Bhd said it has inked an agreement with Innova Bio-Medical Pte Ltd to supply the Sinopharm Covid-19 vaccine to private healthcare practitioners in Singapore.
Innova is part of the Innova Medical Group, a global company specializing in innovative screening, testing and diagnostics for cancer, heart disease, arterial calcification, stroke, and virus detection focused on infectious diseases.
Under the deal, Innova will supply the Chinese-made vaccine to Apex’s wholly-owned unit in Singapore, Apex Pharma Marketing Pte Ltd, for onward sale and distribution to hospitals and private clinics within the city state, said Apex Healthcare.
“Based on confirmed orders, the initial quantity to be supplied is 31,600 doses and is scheduled for arrival in mid-September. Planning is ongoing for future supplies,” the pharmaceutical group added in a bourse filing.
Apex Heathcare said the agreement is not expected to have any material effect on its financial performance.
But it said the initial supply of the Sinopharm vaccine to private healthcare practitioners in Singapore marks the group’s commitment in supporting national vaccination efforts.
Shares of Apex Healthcare closed unchanged at RM3.01 today, valuing the group at RM1.43 billion.